EyeRising and Sky-n1201 reached ANSI group 1 limits within exposure times of 2.8 and 1.4 seconds for a 7-mm pupil.
Enh3ance trial results indicate DTX301 reduces ammonia levels by 18% and supports dietary liberalization in patients with OTC deficiency.
“How do you operationalize what is a coffee flavor versus mocha Frappuccino flavor?” he said. HealthDay News — The Food and Drug Administration (FDA) may allow some flavored e-cigarettes back on the ...
On March 3, the CDC issued a Level 2 travel notice, advising travelers to take extra precautions. The agency says poliovirus is circulating in countries across Africa, the Middle East and Europe.
More patients receiving obinutuzumab vs placebo had primary end point of SLE Responder Index 4. HealthDay News — For patients with systemic lupus erythematosus (SLE), obinutuzumab, a glycoengineered ...
New data show bimekizumab is the first approved biologic to achieve superior outcomes in psoriatic arthritis vs an IL-23 inhibitor.
Increase from 0.16 to 0.44 new monthly dispensations per 1,000 people reported between January 2016 and June 2024 ...
The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of ...
Povetacicept significantly reduced proteinuria in patients with IgA nephropathy in the RAINIER trial, supporting an upcoming FDA submission.
HealthDay News — Testosterone replacement therapy (TRT) before total knee arthroplasty (TKA) is associated with an increased risk for medical and periprosthetic complications, according to a study ...
Desmoda (desmopressin acetate) Vasopressin 2 receptor agonist Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. FDA Approves Desmoda Oral ...
Prasad's stint included several controversial vaccine decisions; the FDA is now searching for a new head for its vaccine division.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results